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A B S T R A C T
This work explores the potential of polymeric micrometer sized devices (microcontainers) as oral drug delivery
systems (DDS). Arrays of detachable microcontainers (D-MCs) were fabricated on a sacriﬁcial layer to improve
the handling and facilitate the collection of individual D-MCs. A model drug, ketoprofen, was loaded into the
microcontainers using supercritical CO2 impregnation, followed by deposition of an enteric coating to protect
the drug from the harsh gastric environment and to provide a fast release in the intestine. In vitro, in vivo and ex
vivo studies were performed to assess the viability of the D-MCs as oral DDS. D-MCs improved the relative oral
bioavailability by 180% within 4 h, and increased the absorption rate by 2.4 times compared to the control. This
work represents a signiﬁcant step forward in the translation of these devices from laboratory to clinic.
1. Introduction
Oral administration of drugs is preferred by patients [1] due to its
inherently reduced invasiveness compared to injections and minimal
need for trained personnel [2,3]. Moreover, the eﬀective healthcare
costs can be diminished avoiding the usage of drugs administered by
injections [4,5].
Following oral administration, drug absorption will occur in the
gastro-intestinal (GI) tract; primarily in the small intestine due to ahigh
surface area provided by the presence of villi and microvilli [6,7].
When delivering drugs through the GI tract, care needs to be taken due
to the presence of enzymes and a low gastric pH (1–3.5 in fasted state
and 3–6 in fed state) [8]. Both of these can have a negative impact on
the administered drug, thereby limiting the eﬀect of the oral formula-
tion.
Traditional oral dosage forms, such as tablets or capsules, can be
designed to target the intestine. Enteric coatings can be used to protect
the dosage form during transit of the stomach and facilitate the delivery
of the drug to the intestinal epithelium for systemic absorption [9,10].
Tablets, capsules as well as micro- and nanoparticulate systems (i.e.
vesicles, polymeric particles and dendrimers) [11–13], manifest an
omni-directional release of the drug in the intestinal lumen. Omni-di-
rectional release entails an inevitable loss of the drug in the lumen and
therefore a reduction of the drug absorbed into the systemic circulation.
Recent and promising approaches focus on reservoir-based micro-
devices serving as drug carriers, potentially bringing the drug to the
desired place of absorption by unidirectional release from the device.
An example of such microdevices is microcontainers. Here a polymeric
cylinder is situated on a ﬂat surface, deﬁning a container structure with
a cavity in the micrometer size [14,15]. Microcontainers provide uni-
directional drug release due to their design and a protection of the drug
formulation from the acidic environment of the stomach. Previously,
they have been suggested as a promising oral drug delivery system, for
instance maintaining indomethacin in its amorphous state [16,17] and
being suitable for the conﬁnement of spray dried lipid nanoparticles
[18]. Furthermore, microcontainers have shown to improve the oral
bioavailability of an amorphous salt of furosemide (a class IV drug in
the Biopharmaceutics Classiﬁcation System (BCS)), compared to the
same drug loaded into a capsule. It was speculated by the authors that
this could be due to the protection of the drug during the passage
through the stomach and because of an engulfment of the micro-
containers in the intestinal mucus, resulting in a prolonged absorption
period [19]. Chirra et al. have illustrated the beneﬁcial eﬀect of using
microdevices to improve the relative oral bioavailability of the BCS
class III drug, acyclovir compared to a solution of the same drug [20].
Moreover, Fox et al. have shown that nanostraw membranes (porous
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nanostructured delivery substrates) increase adhesion to the mucus and
facilitate the drug loading via diﬀusion [21]. So far, the presented
works have only covered part of a device development and/or char-
acterization and, in most cases, not reporting on in vivo studies and not
characterizing the devices and drugs after individual processing steps.
For example, we have previously reported on drug loading of polymer
ﬁlled microcontainers using supercritical carbon dioxide (scCO2) [22].
However, these containers were not detachable and thus, never used in
animal studies. Likewise, we have reported on microcontainers loaded
with powder of furosemide [19] where the ﬁlled containers were me-
chanically removed from the carrier substrate introducing a risk of
damaging the containers.
Here we present, for the ﬁrst time, the complete process of devel-
oping and characterizing a microcontainer-based oral delivery system.
The aim of this work was to translate detachable microcontainers (D-
MCs) ﬁlled with drug and sealed with a lid, from the concept to the ﬁnal
oral DDS suitable for in vivo and ex vivo studies. For this purpose, D-MCs
have been fabricated on a sacriﬁcial layer, improving handling and
facilitating detachment and collection of the individual ﬁlled and
coated D-MCs. D-MCs were loaded with the BCS class II model drug
ketoprofen utilizing scCO2 followed by an enteric coating to prevent
release of the formulation during handling, detachment and transit
through the stomach. The loaded and coated D-MCs were investigated
in vitro to assess the functionality of the enteric lid, and in vivo and ex
vivo, to evaluate the potential of microcontainers as an oral DDS.
2. Materials and methods
2.1. Fabrication of detachable microcontainers (D-MCs)
Silicon (Si) wafers (4-in. b100N n-type) were supplied by Okmetic
(Vantaa, Finland). SU-8 2075 and SU-8 developer were purchased from
Microresist Technology GmbH (Berlin, Germany). Polyacrylic acid
35 wt% aqueous solution (PAA, Mw 100,000) was purchased from
Sigma Aldrich (St. Louis, USA) and neutralized with NaOH. A 15 μm
thick ﬁlm of PAA was spin coated on a Si wafer and dried at 80 °C for
10 min. The PAA ﬁlm served as a water soluble release layer after
completed detachable microcontainers (D-MCs) fabrication [23]. D-
MCs were fabricated with epoxy-based photoresist SU-8 using a pro-
cedure similar to the one described earlier [15,16]. After fabrication,
the wafers were cut into square chips containing 625 D-MCs using a
laser (microSTRUCT vario, 3D Microac AG, Chemnitz, Germany). The
dimensions of the D-MCs were measured using an Alpha-Step IQ Stylus
Proﬁlometer (KLA-Tencor Corporation, Milpitas, USA) and optical mi-
croscopy.
2.2. Loading of drug formulation into the microcontainers
D-MCs sitting on a Si chip were manually loaded with poly-
vinylpyrrolidone (PVP) (Mw= 10,000, Sigma Aldrich, St. Louis, USA)
blowing away the excess in between the D-MCs using an air gun in a
similar setup as described previously [18,19]. The chips were weighted
before and after and placed within a supercritical CO2 chamber (3 chips
at a time, see Fig. 1), together with 14.2 ± 0.1 mg (n = 15, SD) of
ketoprofen powder (≥98% racemate, Sigma Aldrich, St. Louis, USA).
The impregnation of the polymer was conducted by bringing CO2 over
its supercritical state at 100 bar and 40 °C, keeping it under stirring for
1 h. During this process ketoprofen solubilizes in supercritical CO2 and
diﬀuses into the polymer matrix. The pressurization and depressuriza-
tion rate were 3.9 bar/min and 2.5 bar/min, respectively.
2.3. Enteric coating deposition
A pH sensitive polymer, Eudragit® L100 (Evonik, Darmstad,
Germany) was employed for the enteric coating on the cavity of the D-
MCs. A solution of 2% w/v Eudragit® L100 and 5% w/w in relation to
the polymer of dibutyl sebacate (Sigma Aldrich, St. Louis, USA) was
dissolved in isopropanol (Sigma Aldrich, St. Louis, USA).
The solution was sprayed over a chip of drug-loaded micro-
containers using an ultrasonic spray coater equipped with an accumist
nozzle operating at 120 kHz (Sono-Tek, USA). During the procedure,
the ﬂow rate was kept at 0.1 mL/min, together with a 1.5 W generator
power. The shaping air was set to 0.02 bar, and the speed of the nozzle
was maintained at 5 mm/s, keeping a distance between the tip and the
sample of 6.5 cm. The nozzle of the spray coater was positioned above
the chip containing loaded D-MCs, following a path in the x-y axis to
cover an area deﬁned by the corners of the chip, previously identiﬁed
using an integrated camera. Each chip was coated with two alternating
wavy line spray paths having an oﬀset of 2 mm, resulting in a total of
100 passages. The chips were kept at 40 °C during the spray coating
process.
2.4. Morphology characterization
X-ray micro computed tomography (X-ray μCT, Zeiss Xradia 410
versa, Pleasanton, USA) was applied to assess the ﬁlling level of the
ketoprofen:PVP formulation into the D-MCs and the coating mor-
phology on the cavity of the D-MCs. The 3D tomographic reconstruction
was done with the software, provided with the system, based on a FDK
algorithm [24]. The chip with D-MCs was investigated using a high
voltage of 60 kV and having an eﬀective pixel size of 19.33 μm, taking
1601 projection images. For examining smaller parts of the chip with a
higher resolution 60 kV as high voltage and an eﬀective pixel size of
3.02 μm with 3201 projection images was utilized. Three areas from
each sample were analyzed to obtain a more representative image of
the whole chip.
Capsules ﬁlled with D-MCs were scanned to assess the eﬀect of the
collection of the D-MCs after their detachment, to assess if they were
separated one to each other and if the coating was still intact. For this
purpose, scans were recorded with a voltage of 40 kV with a pixel size
of either 10.23 μm or 3.36 μm, taking 1601 projection images.
The quality of both the loading and the coating of the D-MCs was
investigated using a Zeiss Supra 40VP Field Emission Scanning Electron
Microscope (SEM, Carl Zeiss Microscopy GmbH, Jena, Germany). The
samples were placed over metallic holders and tilted to 30° prior the
analyses, both low and high vacuum modes were used with a variable
energy between 4 and 8 keV.
The coating thickness of Eudragit® L100 was measured by contact
proﬁlometry (Alpha-Step IQ Stylus Proﬁlometer, KLA-Tencor
Corporation, Milpitas, USA). Eudragit® L100 ﬁlms were sprayed on a
SU-8 covered ﬂat silicon chip as described in the above section ‘Enteric
Fig. 1. Schematic representation of the supercritical CO2 impregnation process. Within
the chamber the loading of three D-MCs chips due to the solubilization of ketoprofen in
the supercritical CO2 is depicted. On the right, a zoom in of one D-MC during the loading
process is represented.
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coating deposition’. The proﬁles were measured using a 15.6 mg tip
force with a scan speed of 20 μm/s and a sampling rate of 50 Hz.
2.5. Solid state characterization of ketoprofen
X-Ray powder diﬀraction (XRPD) was used to determine the solid
state form of ketoprofen in the D-MCs and of the controls. An X'Pert
PRO X-ray diﬀractometer (PANalytical, Almelo, The Netherlands, MPD
PW3040/60 XRD; Cu KR anode, λ= 1.541 Å, 45 kV, 40 mA) was uti-
lized. A starting angle of 5° 2θ and an end angle of 30° 2θ were em-
ployed for the scans with a scan speed of 0.67335° 2θ/min and a step
size of 0.0262606° 2θ. Data were collected using X'Pert Data Collector
software (PANalytical B.V.). The diﬀractogram of loaded and coated D-
MCs was compared to that of crystalline ketoprofen, coated D-MCs
loaded with crystalline ketoprofen and D-MCs loaded with 1:4 crys-
talline ketoprofen:PVP. The diﬀractograms of D-MCs on the PAA layer,
PVP and Eudragit® L100 were also investigated for comparison (data
not shown). Moreover, XRPD was used to verify the amorphous form of
ketoprofen in the control samples for the in vivo studies (described in
the ‘Capsules preparation’ section).
In addition, the solid state form of ketoprofen impregnated into the
D-MCs and of control formulations was assessed by means of Raman
spectroscopy using a DXR Raman microscope (Thermo Fisher Scientiﬁc,
Inc., Waltham, USA). The microscope was coupled to a single grating
spectrometer with 5 cm−1 FWHM spectral resolution and± 2 cm−1
wavenumber accuracy. All spectra were collected using a laser with a
wavelength of 780 nm, with a 50× objective and an estimated laser
spot of 3.6 μm diameter. A 50 μm slit was utilized when analyzing bulk
powder, whereas a 25 μm pinhole was deployed to analyze the keto-
profen inside the microcontainers the laser power was equal to 10 and
20 mW, respectively. The spectra of: i) pure ketoprofen, ii) pure PVP
and iii) microcontainers ﬁlled with PVP and impregnated with keto-
profen were compared.
2.6. Release of ketoprofen from D-MCs
The eﬃcacy of the coating and its resistance after the detachment of
the D-MCs was evaluated determining the release of the impregnated
ketoprofen, both in a Fasted State Simulated Gastric Fluid
(FaSSGF pH 1.65 – Biorelevant®, London, UK) and Fasted State
Simulated Intestinal Fluid (FaSSIF pH 6.5 – Biorelevant®, London, UK).
Impregnated chips either coated or uncoated were individually im-
mersed in 2 mL of deionized water (pH 3.25) to allow the solubilization
of the PAA layer (avoiding the coating to dissolve) and hence, the de-
tachment of the D-MCs. Suspended D-MCs were transferred into dialysis
bags (MW cut oﬀ: 14,000) and placed in 20 mL of FaSSGF in an orbital
shaking water bath at 37 °C, 150 rpm (Grant Instrument Ltd., model
OLS26, Cambridge, UK) for 2 h. Afterwards, the bags were removed,
rinsed with FaSSIF and placed in 20 mL of fresh FaSSIF at 37 °C,
150 rpm for 6 h. 20 μL were collected at 0, 5, 10, 20, 40, 60, 120 min
during the release in FaSSGF and after 1, 2, 5, 10, 20, 40, 60, 120, 240
and 360 min during the release in FaSSIF. Samples were analyzed using
the UV–Vis spectrophotometer (NanoDrop 2000c, Thermo Fisher
Scientiﬁc Inc., UK) at 258 nm. The amount of ketoprofen loaded in the
D-MCs chips was also investigated as described in the section ‘In vitro
release of ketoprofen from coated D-MCs’. The release curves were
performed at least in triplicates (n = 3 for the coated and n = 6 for the
uncoated D-MCs).
2.7. Capsules preparation
Three chips of D-MCs were impregnated together and coated in-
dividually as described above. The solubilization of the sacriﬁcial layer
and the subsequent detachment from the Si chip were obtained soaking
the chips into 5 mL of deionized water (pH 3.25). After 5 min, the water
was removed and the D-MCs were dried at 37 °C for 15 min. Gelatin
capsules (Torpac® size 9, Fairﬁeld, USA) were ﬁlled with individual D-
MCs (258 ± 31 D-MCs per capsule, as visible in Fig. S5 in the
Supplementary information) and weighted before and after ﬁlling. The
concentration of ketoprofen in the capsules was assessed in vitro by
placing 14 capsules in 20 mL of phosphate buﬀered saline (PBS, Sigma
Aldrich, St. Louis, USA) and kept under stirring (150 rpm) at 37 °C for
24 h. Measurements were done through UV–Vis spectroscopy as de-
scribed before at a wavelength of 258 nm.
The preparation for the control for the in vivo study started with a
physical mixture of ketoprofen and PVP powders with the same weight
ratio (1:4) as in the D-MCs. The mixture was prepared by heating it up
to 120 °C on a heating plate gently mixing the two compounds during
the melting of the drug. The heated mixture was immediately quenched
using liquid nitrogen followed by grinding to a ﬁne powder. The
amorphous form of ketoprofen was conﬁrmed using XRPD as previously
described. Gelatin capsules were loaded with 922.4 ± 11.5 μg of the
grinded powder, an amount corresponding to that of the D-MCs for-
mulation. Subsequently, the capsules were coated with a solution of 5%
w/v Eudragit® L100 and 5% w/w dibutyl sebacate in relation to the
polymer in isopropanol. The capsules were coated by dipping half of it
into the coating solution and dried for 15 min before coating the other
half. This procedure was repeated three times for each capsule.
2.8. In vivo and ex vivo studies
All animal care and experimental studies were performed according
to Danish and European laws, guidelines and policies for animal
housing, care and experiments at the University of Copenhagen. The in
vivo experiment was carried out at the Department of Experimental
Medicine, University of Copenhagen and approved by the local in-
stitutional Animal Welfare Committee under the license number 2015-
15-0201-00454. The ex vivo study was performed at the Department of
Pharmacy, University of Copenhagen under the license number 2016-
15-0201-00892. Both studies were carried out in compliance with the
Danish laws regulating experiments on animals and EC Directive 2010/
63/EU.
Male Sprague-Dawley rats were housed in pairs in cages to accli-
matize for a period of one week with a light/dark period of 12/12 h and
a temperature of 22 °C with a relative humidity of 55 ± 10%. During
this period, the rats had free access to standard pellets and water.
For the in vivo study the rats with a weight ranging from 373 to
436 g were randomly divided into two groups. One group was dosed
with capsules loaded with D-MCs (n = 11), the second group was dosed
with capsules containing the control formulation (n = 6). Both types of
capsules were given using a polyurethane feeding tube (Instech
Laboratories Inc., Plymouth Meeting, USA), one capsule was dosed per
rat. The rats were fastened for 1 h before and after the dosing, and for
the rest of period they had free access to water and standard pellets.
Blood (200 μL) was sampled through the lateral tail vein at 15, 30, 45,
60, 75, 90, 120 min, 4, 6, 8 and 24 h post dosing and collected in
ethylenediaminetetraacetic acid tripotassium salt dihydrate (EDTA,
Sigma-Aldrich, St. Louis, USA) coated tubes. Plasma was obtained by
immediately spinning the blood samples at 1500 g for 10 min. Plasma
was stored at −20 °C until further analyses.
For the ex vivo study, two male Sprague–Dawley rats weighting 316
and 319 g were used and were fasted 1 h prior to dosing.
Capsules ﬁlled with D-MCs (see the section ‘Capsules preparation’)
were administered to the rats by oral gavage as described previously.
After 90 min post-dosing, the rats were sacriﬁced, and opened at the
linea alba for retrieving the stomach and small intestine. These were
immediately cut open and examined for localizing the D-MCs using a
stereo microscope (SteReo Discovery V8, Carl Zeiss MicroImaging
GmbH, Jena, Germany).
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2.9. High Pressure Liquid Chromatography (HPLC) analysis of plasma
samples
HPLC analyses were performed using a Dionex Ultimate 3000 Pump
equipped with a Dionex ASI-100 Automated Sample Injector and with a
UV-VIS lamp.
Ketoprofen was extracted from the plasma samples using a method
described elsewhere [25] with minor modiﬁcations. Brieﬂy, methanol
was added in a 3:1 v/v ratio to the plasma and, after vortexing the
mixtures, the samples were centrifuged at 15,000 g for 6 min and the
supernatants were transferred into HPLC vials.
The HPLC was run in isocratic mode using a method already de-
scribed in literature with slight modiﬁcations [25]. The mobile phases
constituted of (A): deionized water with 1% v/v triﬂuoroacetate (Sigma
Aldrich, St. Louis, USA) and (B): 100% acetonitrile (Sigma Aldrich, St.
Louis, USA). The ratio of the mobile phase A:B was equal to 45:55 v/v.
Samples were run over a Kinetex 5.0 μm XB-C18 100 Å, 100 × 4.6 mm
column (Phenomenex ApS, Nordic Region, Værløse, Denmark) at 22 °C.
The injected volume was 40 μL with a ﬂow rate of 1 mL/min and a total
run time per sample of 10 min. The absorbance was measured at
258 nm.
2.10. Statistics
For the in vivo studies, all results were normalized for the averages
of rat mass and of the ketoprofen dosed.
To calculate the standard error for the area under the curve (AUC,
Table 1), the standard error of the mean of correlated variables is used
=
∑ + ∑ ∑= = ≠SE
var A cov A A
N
[ ] ( , )
AUC
i
M
i i
M
j i
M
i j1 1
where Ai is the AUC for region i.
To calculate the average amount of PVP inside a capsule, and the
associated standard error, the following formula is derived. To derive
the formula, it is assumed that the amount of PVP in each D-MCs in the
ﬁlling process are independently distributed.
= ⎛
⎝
+ + ⎞
⎠N NM
var X var Y
N
var X E Y
M
var Y E X
SE
1 1 [ ] [ ] 1 [ ] [ ] 1 [ ] [ ]
PVP
c
2 2
where Nc is the total amount of microcontainers per chip, X is the total
amount of PVP measured N times, and Y is the number of micro-
containers contained inside a capsule, measured M times.
The raw data of the in vivo studies can be found in the
Supplementary information (Fig. S4).
Moreover, as the sample sizes are diﬀerent the eﬀect sizes reported
in Table 1 uses the Hedges g eﬀect size deﬁned as g=(M1−M2)/
SDpooled where SDpooled is the weighted standard deviation of the two
groups [26–28].
All of the data are expressed as mean and the usage of standard
deviation (SD) or standard error of the mean (SE) is deﬁned within the
text. Where appropriate, statistical analysis was carried out using
Student t-tests using GraphPad Prism version 6.05. P-values below 5%
(p < 0.05) were considered statistically signiﬁcant.
3. Results
3.1. Fabrication of microcontainers on a sacriﬁcial layer
D-MCs were successfully fabricated in SU-8 on a water soluble layer
of PAA. D-MCs had a height of 304 ± 12 μm (n = 8, SD) and a dia-
meter equal to 329 ± 5 μm (n = 8, SD). The inner reservoir had a
depth of 272 ± 6 μm (n = 8, SD) and a diameter of 188 ± 4 μm
(n = 8, SD) resulting in a container volume of 7.5 ± 0.3 nL (n = 8,
SD). D-MCs were adhering well to the PAA layer not impairing the
handling. D-MCs were arranged in arrays of 25 × 25 devices on
quadratic chips with a side length of 12.8 mm.
Fig. 2. Morphological characterization of drug loaded D-
MCs. (a) and (b): SEM images of D-MCs ﬁrst manually
loaded with PVP and then impregnated with ketoprofen in
supercritical CO2 at 40 °C and 100 bar for 1 h. (c):X-ray μCT
cross-sectional view of the loaded D-MCs.
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3.2. Loading of D-MCs
Every chip with D-MCs was manually ﬁlled with 1.79 ± 0.21 mg
(n = 54 chips, SD) of PVP powder followed by loading ketoprofen into
the polymer matrix using scCO2. All chips underwent the same super-
critical treatment at 40 °C and 100 bar for 1 h. The ﬁlled D-MCs on
chips were visualized using a SEM (Fig. 2a, b). The cross-sectional X-ray
μCT image of the D-MCs loaded with PVP and ketoprofen is shown in
Fig. 2c.
3.3. Enteric coating deposition onto drug-loaded D-MCs
The spray coated gastro-resistant lid of Eudragit® L100 was, in-
itially, characterized using contact proﬁlometry to deﬁne the coating
thickness on two chips. This resulted in thicknesses of 123.0 ± 1.9 and
118.7 ± 3.3 μm (SD describes the roughness of the surface of the
coating). X-Ray μCT and SEM were utilized to assess the morphology of
the coatings after their deposition on the cavity of the D-MCs. The
coatings were homogenous (Fig. 3a, b) and well distinguishable from
the impregnated PVP and ketoprofen (Fig. 3c).
3.4. In vitro release of ketoprofen from coated D-MCs
The detachment of the drug-loaded and coated D-MCs from the PAA
layer was accomplished by soaking chips in deionized water at pH 3.25
for about 5 min.
The release of ketoprofen was evaluated in human FaSSGF for
120 min (simulating the residence time in the stomach) followed by
investigation of the drug release in human FaSSIF for 360 min (simu-
lating the transit time of the small intestine). After 120 min in FaSSGF,
56 ± 14% of the loaded ketoprofen from uncoated D-MCs was re-
leased compared to 16 ± 3% from the coated D-MCs (Fig. 4). Upon
changing to FaSSIF, a burst release with a signiﬁcant immediate con-
centration diﬀerence was noticed for the coated microcontainers (p-
value = 0.0022). After 6 h in FaSSIF, 100% of the loaded ketoprofen
was released from both the coated and uncoated D-MCs. The release
proﬁle of ketoprofen for the uncoated D-MCs did not present a burst
release, but instead followed a ﬁrst order kinetic. Consequently, sta-
tistical signiﬁcance (p-value = 0.002) was noticeable for the release of
ketoprofen after 2 h between coated and uncoated D-MCs. The total
amount of ketoprofen loaded into a single chip with 625 D-MCs was
424 ± 10 μg (n = 14, SE) corresponding to a weight ratio of
Fig. 3. Morphological characterization of loaded and
coated D-MCs. (a) and (b):SEM images of D-MCs coated
with Eudragit® L100 onto the cavity of the drug-loaded D-
MCs. (c): X-ray μCT cross-sectional view of the drug-loaded
and coated D-MCs.
Fig. 4. In vitro cumulative release of ketoprofen. Coated (red line) and uncoated (black
line) D-MCs. For the ﬁrst 120 min, the chips were placed in FaSSGF and subsequently in
FaSSIF for 360 min. Each release curve is calculated as mean ± standard deviation
(n = 6 for the uncoated D-MCs, n = 3 for the coated D-MCs). For the individual proﬁles
refer to Fig. S3 in the Supplementary information. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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ketoprofen to PVP of approximately 1:4 (see the ‘Formulation pre-
paration for in vivo and ex vivo studies’ section). The total amount of
ketoprofen loaded into the coated and uncoated D-MCs were seen to be
very similar. No signiﬁcant diﬀerence was found (p-value = 0.2542).
3.5. Solid state characterization of ketoprofen in D-MCs
The solid state form of ketoprofen in the D-MCs both after scCO2
impregnation and after additional enteric coating deposition was
evaluated by means of XRPD. By comparing the diﬀractograms
(Fig. 5a), it was found that the distinct peaks of crystalline ketoprofen
were not visible in the ﬁnal scCO2 impregnated and coated micro-
containers. This, together with the typical scattering halo (Fig. 5a, red),
indicated the maintenance of ketoprofen in its amorphous form within
the D-MCs. The two controls (coated D-MCs loaded with crystalline
ketoprofen and D-MCs with a crystalline ketoprofen:PVP mixture in the
ratio 1:4) demonstrated that it was possible to measure through the
coating and to detect crystalline ketoprofen in the D-MCs in the same
quantity as seen in the scCO2 impregnated and coated microcontainers
(Fig. 5a, blue and green).
It is worth mentioning that the melted and quenched mixture of
ketoprofen:PVP 1:4 (used as control for the in vivo studies) was also
found to be amorphous in the XRPD diﬀractograms (see in
Supplementary information Fig. S1).
The XRPD results were corroborated by Raman spectroscopy
comparing the spectra of pure crystalline ketoprofen, pure PVP and
microcontainers ﬁlled with PVP and impregnated with ketoprofen
(Fig. 5b). As noticeable from the Raman spectra, the characteristic vi-
brational patterns of ketoprofen were also visible in the impregnated D-
MCs. Brieﬂy, the intensity of the peak at 1657 cm−1, which is attrib-
uted to the vibrational stretch of the carbonyl ν(C]O), decreased
compared to that of crystalline ketoprofen. Moreover, the broadening of
the band around 1198 cm−1 (CH ring plane bending) together with the
lowering of the peak intensities between 1500 cm−1 and 1100 cm−1,
supported the hypothesis of ketoprofen amorphization due to the im-
pregnation process [29].
3.6. Formulation preparation for in vivo and ex vivo studies
Gelatin capsules were ﬁlled with 258 ± 31 (n = 54, SE) scCO2
loaded and coated D-MCs corresponding to 176 ± 14 μg (n = 14, SE)
of ketoprofen and 741 ± 52 μg (n = 54, SE) of PVP.
X-ray μCT was employed to visualize the microcontainers inside the
capsule. It can be seen that the coating was preserved through all
preparation steps and that the microcontainers were intact and sepa-
rated from each other (Fig. 6).
3.7. In vivo studies
Capsules ﬁlled with D-MCs or with the control formulation were
Fig. 5. Solid state characterization of ketoprofen in D-MCs. (a)
XRPD diﬀractograms of crystalline ketoprofen (black), D-MCs
impregnated with ketoprofen and coated (red), D-MCs loaded
with crystalline ketoprofen and coated (blue) and D-MCs loaded
with 1:4 crystalline ketoprofen:PVP (green). (b) Raman scat-
tering proﬁles of PVP powder (blue), crystalline ketoprofen
(black) and D-MCs impregnated with ketoprofen (red). (For in-
terpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
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dosed by oral gavage to rats. The measured plasma concentration of
ketoprofen over time is presented in Fig. 7 and key results are sum-
marized in Table 1. The maximum plasma concentrations (Cmax) are
similar for D-MCs and the control. The values were found to be
657 ± 78 ng/mL and 488 ± 105 ng/mL for the formulation with D-
MCs and for the control, respectively (p-value = 0.2191). The AUC
from 0 to 24 h (AUC0-24h) was calculated to be 406 ± 40 min·ng/mL
for the D-MCs formulation and 320 ± 49 min·ng/mL for the control,
thereby, no signiﬁcant diﬀerence was observed between the two groups
(p-value = 0.2041). The relative bioavailability from 0 to 24 h
for ketoprofen in D-MCs compared to the control was found
to be 127 ± 23%. However, statistically relevant diﬀerence
(p-value = 0.0279) was found for the time corresponding to the max-
imum plasma concentration (Tmax) when comparing the two formula-
tions (93 ± 17 min for the D-MC and 212 ± 60 min for the control).
The AUC0-4h for the D-MCs formulation was 99 ± 10 min·ng/mL and
55 ± 18 min·ng/mL for the control resulting in a statistically sig-
niﬁcant diﬀerence between the two groups (p-value = 0.0387). Ac-
cording to this, the oral relative bioavailability from 0 to 4 h was
180 ± 62% for the D-MC formulation compared to the control. The
absorbance rate of ketoprofen (C0 to Cmax) for the rats dosed with D-
MCs was 10 ± 2 ng·min−1·mL−1, which is signiﬁcantly higher than
for the control (4 ± 1 ng·min−1·mL−1) (p-value = 0.0430, Fig. 7, top
right).
3.8. Ex vivo study
In order to understand the mechanism of action of the D-MCs, their
position in the GI tract of the rats at Tmax (90 min) was assessed. No D-
MCs were found in the stomach of the rats at Tmax, whereas many were
found in the mid-jejunum (see Fig. S2 in the Supplementary informa-
tion). This indicates that the enteric coating protected the formulation
until the intestine was reached, where the ketoprofen was released and
absorbed.
4. Discussion
Micro- and nanotechnologies are enabling new possibilities in the
world of oral drug delivery. It is a highly complex and multidisciplinary
ﬁeld with focus on fabrication and on the possibilities to integrate novel
functionalities into drug delivery systems. In vivo studies proving their
actual performances [21,30–32] are, however, not always carried out.
In this work, an oral DDS based on microcontainers has been further
developed compared to previous ones [19,33]. The complete process,
starting from the fabrication of the new D-MCs to the loading and
coating, highlighting the subsequent results from the in vivo and ex vivo
investigations, is presented.
D-MCs were ﬁlled with PVP in a simple and reproducible manner
and scCO2 was used to load the D-MCs with the model drug ketoprofen
with a ﬁnal 1:4 weight ratio of drug to polymer. A single D-MC has a
cavity of 7.5 ± 0.3 nL, 178 times larger compared to other similar DDS
[34], and each one was loaded with 0.68 μg of ketoprofen, which is
considerably more compared to the data presented by Chirra et al.
(1.54 ng) [20]. The amount of ketoprofen in a single D-MC corresponds
to 1.3% w/w of the total weight of the microdevice. The technique of
scCO2 impregnation was preferred over inkjet printing due to the low
spotting reproducibility and low loading capacity of the printing pro-
cess [35,36].
In the loading process, scCO2 acts as a solvent for ketoprofen, but
not for PVP, which only swells [22]. The porosity of PVP increased
during the impregnation allowing ketoprofen to access the D-MCs. CO2,
in its supercritical state, has a density similar to a liquid, whereas the
viscosity and diﬀusivity are closer to the ones of a gas. These features
are exploited during the impregnation process, where ketoprofen is
used in relatively high concentration and diﬀuses easily with the CO2
into the D-MCs.
Fig. 6. X-ray μCT image of a gelatine capsule ﬁlled with loaded and coated D-MCs.
Fig. 7. Plasma concentration of ketoprofen over time. (Red line), capsules with loaded
and coated D-MCs (n = 11, SE). (Black line), control capsules ﬁlled with melted keto-
profen and PVP and coated (n = 6, SE). The inset represents the same proﬁles zoomed in
the ﬁrst 4 h. For the individual proﬁles refer to Fig. S4 in the Supplementary information.
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
Table 1
Non-compartmental model of the in vivo study of ketoprofen in D-MCs (n = 11, SE) and for the control formulation (n = 6, SE).
Capsule with loaded and coated D-MCs Coated capsules with 1:4 ketoprofen:PVP amorphous mixture (control) Eﬀect sizeb
Cmax [ng/mL] 657 ± 78 488 ± 105 0.65
Tmax [min] 93 ± 17a 212 ± 60a 1.24
AUC0-4h [min·ng/mL] 99 ± 10a 55 ± 18a 1.16
AUC0-24h [min·ng/mL] 406 ± 40 320 ± 49 0.68
Relative oral bioavailability [%]
0–4 h 180 ± 62%
0–24 h 127 ± 23%
a p-value < 0.05.
b Eﬀect size=(M1−M2)/SDpooled where M1 and M2 are the averages of the two populations andSDpooled is the weighted standard deviation of the two groups.
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During the scCO2 impregnation, a solid state transition of keto-
profen from its crystalline to its amorphous form was obtained.
Ketoprofen is a BCS class II drug meaning that it has a poor solubility in
water. Therefore, its aqueous solubility can be increased by exploiting
the amorphous form [37–40]. The XRPD diﬀractograms and the Raman
spectra (Fig. 5a and b, respectively) suggested that the amorphous form
of ketoprofen was present after impregnation into the D-MCs, con-
ﬁrming previous results [33].
Ketoprofen was kept in its amorphous form for at least 7 days (data
not shown) due to the use of scCO2 and to its aﬃnity with PVP
[29,41,42]. PVP is a water soluble polymer and has unique properties in
prolonging the stability of amorphous forms of drugs, thereby in-
creasing their dissolution rate and solubility [41]. Microcontainers can
additionally stabilize the amorphous form of drugs by spatially con-
ﬁning the drug molecules, leading to an improved physical stability of
the amorphous drugs [16,17].
In order to avoid premature release of ketoprofen, D-MCs were
coated with the gastro-resistant polymer Eudragit® L100. The in vitro
dissolution studies (Fig. 4) conﬁrmed that this polymer successfully
protected the drug during transit through the gastric environment and
dissolved quickly upon arrival in the small intestine (where the pH is
generally above 6) [19,43–46]. Spray coating by an ultrasonic nozzle
was selected as the technology to deposit the coating onto the cavity of
the D-MCs. The morphology of PVP and ketoprofen after impregnation
(Fig. 2) was suitable for the coating deposition as there was still space
for the coating in the top of the cavity of the D-MCs. The deposition of
the lid was simple and straightforward, and has the potential of being
scaled up. D-MCs were detached from the fabrication platform by
soaking them into acidiﬁed water. This approach maintains the in-
tegrity of the gastro-resistant lid (Fig. 6) and it is a gentler and more
controlled procedure than using, for example, mechanical forces. SEM
images and X-ray μCT scans of coated D-MCs showed that after spray
coating no agglomerates of polymer were present between adjacent
microcontainers and that the D-MCs were not attached to each other
after dissolution of the PAA sacriﬁcial layer (Figs. 3 and 6).
The in vitro release of ketoprofen from the D-MCs in gastric and
intestinal simulated media demonstrated the eﬃcacy of the coating.
The immediate release of 16 ± 3% of ketoprofen from the coated D-
MCs in FaSSGF can be explained by the presence of small pores in the
coating (Fig. 3) and/or the possible variation of the polymer mor-
phology (refer to the video in the Supplementary Information for a
more detailed view). For the uncoated D-MCs, 56 ± 14% of ketoprofen
was released in FaSSGF, showing that nothing eﬃciently hindered the
drug release. Coated D-MCs showed a very signiﬁcant burst release
upon changing to FaSSIF due to the dissolution of Eudragit® L100 fol-
lowed by a fast release of ketoprofen, together with dissolution of PVP
(Fig. 4).
In vivo studies are necessary when testing new drug delivery systems
as they provide indications on possible bioavailability improvements
after oral administration compared to a control formulation [47,48].
The control formulation used in these studies was designed to have
the same ratio of ketoprofen:PVP (1:4) and a total amount of drug and
polymer as for the D-MCs formulation to obtain information on the
behavior of the D-MCs. The solid state form of a drug has a large in-
ﬂuence on the dissolution rate, and can therefore, be of great im-
portance for the bioavailability [49]. It was found that ketoprofen in the
D-MCs after scCO2 impregnation was amorphous and consequently, the
ketoprofen in the control formulation was also brought to its amor-
phous form. This was obtained by melting the ketroprofen together
with PVP followed by a fast cooling, which is a common method for
preparing the amorphous form of a drug, as reported by Enfalt et al.
[50].
Compared to the control, the D-MCs formulation did not provide a
higher Cmax. However, a faster Tmax was observed for the D-MCs for-
mulation being roughly 2.3 times faster than the control. This sig-
niﬁcant diﬀerence resulted in a large value for the eﬀect size (Table 1),
in accordance with the classiﬁcation proposed by Choen [28], where
the intervals 0.00–0.20, 0.20–0.50 and 0.50–0.80 correspond to a small,
medium or large eﬀect, respectively. This indicates that D-MCs have a
large eﬀect on the time of absorption. For the ﬁrst 4 h of the plasma
concentration-time proﬁle (Fig. 7), the absorption of ketoprofen was
signiﬁcantly higher than for the control, again resulting in a large eﬀect
size value (Table 1). This diﬀerence resulted in a relative oral bioa-
vailability of 180 ± 62% for the ﬁrst 4 h. In accordance with the dif-
ference between the Tmax values, the absorption rate was signiﬁcantly
higher for the rats administered with D-MCs compared to the control
rats. This supports the conclusion that the D-MCs provided a much
faster absorption of ketoprofen compared to the control. It can be hy-
pothesized that this, to some extent, is caused by a faster gastric emp-
tying of the rats dosed with the D-MCs compared to the control. Indeed,
D-MCs were most likely released from the gelatin capsule in the sto-
mach as no coating was applied to the entire capsule, conversely to the
control formulation. From the plasma concentration curve (Fig. 7), it is
noticeable that after 4 h the two formulations show more similar ki-
netics, and the AUC0-24h is not signiﬁcantly diﬀerent. This is reﬂected in
the relative bioavailability of ketoprofen in the D-MCs formulation
compared to the control being 127 ± 23%. Choi et al. [51] evaluated
the intestinal absorption of a suspension of ketoprofen in rats admin-
istering a 2.3 times higher dosage compared to the one used in the
present study. The authors report a higher Cmax (6.12 ± 1.02 μg/mL)
and a faster Tmax (0.42 ± 0.29 h). Indeed, these results might be at-
tributed to the higher dosage and to the fact that ketoprofen was dosed
in a suspension form, thus, partially pre-solubilized. An important dif-
ference comparing these two studies is the plasma concentration decay
over time. The decrease is slower for the D-MCs, indicating a prolonged
drug release and absorption time. A possible explanation for this might
be provided by the results of our ex vivo study where at the time in
which the Tmax was reached (93 ± 17 min), D-MCs were spread in the
small intestine, and most of them were found in the mid-jejunum em-
bedded deep into the mucus. This pronounced engulfment might indeed
have resulted in a slower release and at the same time allowed pro-
longed absorption of ketoprofen. It has previously been shown in in-
testinal perfusion studies in rats that SU-8 microcontainers have mu-
coadhesive properties showing i.e. a high tendency to be engulfed by
the mucus [19].
5. Conclusions
In this work, we demonstrated that D-MCs are a promising oral drug
delivery system providing a 2.3 times faster Tmax and a 180% increased
AUC0-4h when compared to the control. These features can be of high
importance as it could imply that the administered dose could be re-
duced. The BCS class II model drug ketoprofen was successfully loaded
into D-MCs exploiting the features of scCO2 impregnation maintaining
the API in its amorphous form. Enteric coating was employed to protect
the drug from the stomach environment and to release ketoprofen in
the intestine, as proven by the in vitro study. All preparation steps are
designed to be compatible with each other maintaining ketoprofen in its
amorphous state. In vivo and ex vivo analyses ﬁnally show the potentials
of using D-MCs as an oral drug delivery system.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jconrel.2017.10.013.
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